Erstellt von fchar99
Moleculin Biotech Inc diskutieren
Moleculin Biotech Inc
WKN: A2QQM0 / Symbol: MBRX / Name: Moleculin Biotech / Aktie / Pharmazeutika / Micro Cap /
0,41 €
1,53 %
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its price target lowered by analysts at Maxim Group from $20.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat
Moleculin Biotech, Inc. (NASDAQ: MBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Ratings data for MBRX provided by MarketBeat
Neueste Beiträge
Roth_Capital in Discuss Vicor Corp.